Pay attention to the prevention and supervision of kidney injury related to sodium-glucose transporter 2 inhibitors
10.3760/cma.j.cn114015-20240528-00368
- VernacularTitle:重视钠-葡萄糖共转运蛋白2抑制剂相关肾损伤的防范与监管
- Author:
Liwei JI
1
Author Information
1. 北京医院药学部/国家老年医学中心/中国医学科学院老年医学研究院/北京市药物临床风险与个体化应用评价重点实验室，北京 100730
- Publication Type:Journal Article
- Keywords:
Sodium-glucose transporter 2 inhibitors;
Acute kidney injury;
Dibabetes mellitus, type 2;
Heart failure;
Chronic kidney disease;
Pharmacovigilance;
Artifici
- From:
Adverse Drug Reactions Journal
2025;27(3):142-146
- CountryChina
- Language:Chinese
-
Abstract:
Sodium-glucose transporter 2 inhibitors (SGLT2i) are currently widely used as a class of hypoglycemic drugs. Due to their unique hypoglycemic mechanism and significant cardio-renal protective effect, SGLT2i have become one of the core drugs in the treatment of type 2 diabetes mellitus. However, in recent years, it has been found that SGLT2i can lead to increased serum creatinine and urea nitrogen in some patients, and the risk of kidney injury has gradually attracted clinical attention. How to effectively prevent and supervise the potential renal injury risk while giving full play to its therapeutic advantages has become an important topic in current clinical practice and drug safety management. Multi-dimensional prevention and supervision strategies should be adopted in clinical practice such as identifying high-risk populations based on the latest evidence, strictly screening patients, dynamically monitoring renal function, optimizing combination medication regimens, and achieving risk warning using biomarkers and artificial intelligence tools.
